Publications

IOP Lowering Ability of NB-1111 active moiety, THC, in a human tissue

American Academy of Ophthalmology (AAO) 2019

IOP Profiles Following Single-Dose Δ9- Tetrahydrocannabinol-Valine-Hemisuccinate (NB1111) Nanoemulsion and Latanoprost

American Academy of Ophthalmology (AAO) 2019

Bioavailability of Δ9- Tetrahydrocannabinol (Δ9- THC) from Different Dosage Forms Containing its Prodrug Δ9- THC-VAL-HS (NB1111)

International Cannabinoid Research Society (ICRS) Symposium 2018

Intraocular Pressure Lowering Efficacy of Δ9- Tetrahydrocannabinol Prodrug, NB1111, in a Normotensive Rabbit Model

International Cannabinoid Research Society (ICRS) Symposium 2017

Analogue Derivatization of CBD For Improved Ocular Permeation: In Vitro and In Vivo Evaluation

American Association of Pharmaceutical Scientists (AAPS) 2017

Intraocular Pressure Lowering Activity of Δ9- Tetrahydrocannabinol in α- Chymotrypsin Induced Glaucoma Model: Dose-Effect Relationship

American Association of Pharmaceutical Scientists (AAPS) 2014

Development of Δ9- Tetrahydrocannabinol Prodrug with Improved IOP Lowering Efficacy

American Association of Pharmaceutical Scientists (AAPS) 2014

Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability

Effect of surfactant concentration and sterilization process on intraocular pressure-lowering activity of Δ 9-tetrahydrocannabinol-valine-hemisuccinate (NB1111) nanoemulsions

Analog Derivatization of Cannabidiol for Improved Ocular Permeation

Effects of Cannabidiol and a Novel Cannabidiol Analog against Tactile Allodynia in a Murine Model of Cisplatin-Induced Neuropathy: Enhanced Effects of Sub-Analgesic Doses of Morphine

Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits